These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2894431)

  • 1. Proglumide, a cholecystokinin receptor antagonist, exacerbates alloxan-induced diabetes mellitus in Swiss mice.
    Parmar NS; Tariq M; Ageel AM
    J Pharm Pharmacol; 1987 Dec; 39(12):1028-30. PubMed ID: 2894431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proglumide antagonizes cholecystokinin effects on plasma glucose and insulin in rats in vivo.
    Verspohl EJ; Wunderle G; Ammon HP
    Eur J Pharmacol; 1988 Jul; 152(1-2):121-8. PubMed ID: 3208828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proglumide (gastrin and cholecystokinin receptor antagonist) inhibits insulin secretion in vitro.
    Verspohl EJ; Wunderle G; Ammon HP; Williams JA; Goldfine ID
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):284-7. PubMed ID: 3012373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice.
    Karlsson S; Ahrén B
    Acta Physiol Scand; 1989 Mar; 135(3):271-8. PubMed ID: 2648765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of proglumide on rat pancreatic growth.
    Yamaguchi T; Tabata K; Johnson LR
    Am J Physiol; 1985 Aug; 249(2 Pt 1):G294-8. PubMed ID: 2411150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of proglumide on cholecystokinin-, bombesin-, and glucagon-induced satiety in the rat.
    Collins S; Walker D; Forsyth P; Belbeck L
    Life Sci; 1983 May; 32(19):2223-9. PubMed ID: 6843294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice.
    Suh HH; Tseng LF
    Eur J Pharmacol; 1990 Apr; 179(3):329-38. PubMed ID: 2142090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats.
    Shillabeer G; Davison JS
    Am J Physiol; 1987 Feb; 252(2 Pt 2):R353-60. PubMed ID: 3812772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of proglumide on pancreatic acinar cell function.
    Williams JA; Bailey A; Steigerwalt RW
    Digestion; 1983; 27(4):227-33. PubMed ID: 6197332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the cholecystokinin antagonist, proglumide, on prolactin secretion in the rat.
    Vijayan E; McCann SM
    Life Sci; 1987 Feb; 40(7):629-34. PubMed ID: 3807652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of proglumide and CR 1409, a new glutaramic acid derivative, on CCK-8-induced pancreatic polypeptide and insulin secretion in the dog.
    Inui A; Oya M; Inoue T; Sakatani N; Morioka H; Baba S
    Horm Metab Res; 1988 Jan; 20(1):61-2. PubMed ID: 3286447
    [No Abstract]   [Full Text] [Related]  

  • 12. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues.
    Niederau C; Niederau M; Williams JA; Grendell JH
    Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural features of various proglumide-related cholecystokinin receptor antagonists.
    Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
    Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide.
    Watkins LR; Kinscheck IB; Mayer DJ
    Brain Res; 1985 Feb; 327(1-2):169-80. PubMed ID: 3838690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide.
    Chiodo LA; Freeman AS; Bunney BS
    Brain Res; 1987 May; 410(2):205-11. PubMed ID: 3036308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of vagotomy on the increase in food intake induced by the cholecystokinin antagonist, proglumide.
    Shillabeer G; Davison JS
    Regul Pept; 1985 Oct; 12(2):91-9. PubMed ID: 4070688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment.
    Kellstein DE; Mayer DJ
    Brain Res; 1990 May; 516(2):263-70. PubMed ID: 2364292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central and peripheral proglumide administration and cholecystokinin-induced satiety.
    Willis GL; Hansky J; Smith GC
    Regul Pept; 1986 Aug; 15(1):87-98. PubMed ID: 3532220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
    Inui A; Inoue T; Sakatani N; Oya M; Morioka H; Baba S
    Brain Res; 1987 Aug; 417(2):355-9. PubMed ID: 3651819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin octapeptide, proglumide, and passive avoidance in rats.
    Deupree D; Hsiao S
    Peptides; 1987; 8(1):25-8. PubMed ID: 3575151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.